Transformed streptomyces bacteria and method for producing bioactive substance with c-p bond

By introducing a modified phpR gene with optimized codons into Streptomyces bacteria, the production of physiologically active substances with C-P bonds is enhanced, addressing inefficiencies in existing methods and improving the yield of substances like bialaphos.

JP2024158713AInactive Publication Date: 2024-11-08IDEMITSU KOSAN CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023074126
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-28
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for producing physiologically active substances with C-P bonds, such as bialaphos, are not efficient enough, and there is a need for improved production systems to meet the demand for environmentally friendly herbicides.

Method used

Introducing a modified phpR gene with specific codon structures into Streptomyces bacteria to enhance the production of physiologically active substances with C-P bonds, such as bialaphos, by optimizing gene expression and codon usage.

Benefits of technology

The modified phpR gene significantly enhances the production of substances like bialaphos, achieving up to 2.5 times the productivity compared to unmodified strains, making it a more efficient method for producing environmentally friendly herbicides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024158713000001_ABST
    Figure 2024158713000001_ABST
Patent Text Reader

Abstract

To provide a technique to efficiently produce bioactive substances with C-P bonds, such as bialaphos, with actinomycetes.SOLUTION: The present invention provides Streptomyces bacteria that include a modified phpR gene and exhibit enhanced production of bioactive substances with C-P bonds, where the modified phpR gene is a gene encoding a polypeptide consisting of a specific amino acid sequence, and the codons of the modified phpR gene are specific codons for phenylalanine, leucine, isoleucine, valine, serine, proline, threonine, alanine, tyrosine, histidine, glutamine, asparagine, lysine, aspartic acid, glutamic acid, cysteine, arginine, and glycine, with the stop codon being UGA.SELECTED DRAWING: Figure 3
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates generally to the microbial industry, and more particularly to Streptomyces bacteria that contain a modified phpR gene and have enhanced production of bioactive substances having CP bonds, such as bialaphos. [Background technology]

[0002] In general, chemically synthesized pesticides are widely used as herbicides because they are stable, highly effective, and cost-effective. However, in recent years, from the viewpoint of environmental load, there is an increasing demand for herbicides derived from microbial metabolites to replace chemically synthesized pesticides. Herbicides derived from microbial metabolites are natural products, and therefore generally have the advantages of being highly biodegradable and having low environmental load.

[0003] Known herbicides derived from microbial metabolites include the amino acid herbicide bialaphos. Bialaphos is a herbicide derived from Streptomyces ( Streptomyces It is a secondary metabolite produced by actinomycetes belonging to the genus Streptomyces, e.g., Streptomyces hygroscopicus ( Streptomyces hygroscopicus It has been reported that bialaphos can be produced by the method of fermentation (Non-Patent Document 1). It has also been reported that the productivity of bialaphos has been improved by mutation breeding (Non-Patent Document 2).

[0004] The synthesis of bialaphos involves the bialaphos synthesis gene cluster, and it is known that there are transcription factors that control the genes of the bialaphos synthesis gene cluster. For example, the brpA gene (a homologue of the phpR gene) of Streptomyces hygroscopicus is one of the genes that constitute the bialaphos synthesis gene cluster, and is known to be a transcription factor that controls the genes in the cluster (Non-Patent Document 3). In addition, the prpA gene (another name for the phpR gene) of Streptomyces viridochromogenes is one of the genes that constitute the bialaphos synthesis gene cluster, and is a transcription factor that controls the genes in the cluster, but it is known that overexpression of the prpA gene does not increase the production of bialaphos (Non-Patent Document 4). [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Tachibana K. et al., 1986, Journal of the Pesticide Science Society of Japan, 11, 297-304 [Non-Patent Document 2] Takebe et al., 1995, Journal of Bioengineering, 73, 413-24 [Non-Patent Document 3] Anzai H. et al., Journal of Bacteriology, 1987, 169(8), 3482-3488 [Non-Patent Document 4] Schwartz D. et al., 2004, Applied and Environmental Microbiology, 70, 7093-7102 Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention relates to a transformant having improved productivity of a physiologically active substance having a CP bond, such as bialaphos. The objective of the present invention is to provide a recombinant Streptomyces bacterium and a method for producing a physiologically active substance using the transformed Streptomyces bacterium. [Means for solving the problem]

[0007] As a result of intensive research conducted by the present inventors to solve the above problems, it has been found that by introducing a modified phpR gene having a specific codon configuration into a bacterium of the genus Streptomyces, it is possible to express C- The present invention was completed based on the discovery that the productivity of physiologically active substances having P bonds can be improved. I did.

[0008] The present invention provides the following: [1] A strain containing a modified phpR gene and capable of enhancing the production of a physiologically active substance having a CP bond. Ptomyces ( Streptomyces ) bacteria, The modified phpR gene is a gene encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1, The codons of the modified phpR gene are UUC for phenylalanine, CUG or CUC for leucine, Isoleucine is AUC, valine is GUC or GUG, serine is UCG, UCC or AGC, proline is CCG or CCC, threonine is ACC or ACG, alanine is GCC or GCG, and tyrosine is UAC. , histidine is CAC, glutamine is CAG, asparagine is AAC, lysine is AAG, aspartic acid is GAC, glutamic acid is GAG, cysteine ​​is UGC, arginine is CGC or CGG, glycine is GGC, and the stop codon is UGA, in bacteria. [2] The codons of the modified phpR gene are UUC for phenylalanine, CUG for leucine, AUC for isoleucine, GUC for valine, UCG for serine, CCG for proline, ACC for threonine, and ALC for alanine. GCC for tyrosine, UAC for histidine, CAC for glutamine, CAG for asparagine, AAC for lysine, and AAC for lysine. The codon is AAG, aspartic acid is GAC, glutamic acid is GAG, cysteine ​​is UGC, arginine is CGC, glycine is GGC, and the stop codon is UGA. [3] The bacterium described in [1] or [2], wherein the modified phpR gene is a polynucleotide comprising the base sequence of SEQ ID NO: 2. [4] Streptomyces viridochromogenes ( Streptomyces viridochromogenes ) or Streptomyces hygroscopicus ( Streptomyces hygroscopicus The bacterium according to any one of [1] to [3], which is a bacterium belonging to the Bacillus subtilis. [5] The physiologically active substance having a CP bond is bialaphos, L-glufosinate, dehydrophos Selected from the group consisting of Dehydrophos, Fosfomycin and FR900098 The bacterium according to any one of [1] to [4], wherein the bacterium is one or more species that can be detected by the method. [6] Any of [1] to [5], wherein the physiologically active substance having a CP bond is bialaphos. The bacterium described above. [7] A method for producing a physiologically active substance having a CP bond, comprising the steps of: A production method comprising culturing the bacterium according to any one of [1] to [6] in a culture medium to produce and accumulate bialaphos in the culture medium and / or the bacterial cells. Effect of the Invention

[0009] According to the present invention, by introducing a modified phpR gene having a specific codon structure into a bacterium of the genus Streptomyces, it is possible to efficiently produce a physiologically active substance having a CP bond, such as bialaphos, through fermentation. It can be produced. [Brief description of the drawings]

[0010]

Figure 1

Figure 2

Figure 3

Figure 4

[0011] In this specification, the strains with accession numbers beginning with the word JCM are registered with the Japan Collection of Microorganisms (RIKEN BioResource Center, Microbial Materials Research Center). Microorganisms stored in the Laboratory of Microorganisms (Hokkaido University, Tsukuba City, Ibaraki Prefecture, Japan, Postal Code: 305-0074, Address: 3-1-1 Takanodai, Tsukuba City, Ibaraki Prefecture) The number is assigned to the organization and is available from the organization.

[0012] As used herein, strains having accession numbers beginning with the word ATCC can be obtained from the American Type Culture Collection (Address: 10801 University Boulevard Manassas, VA 20110, United States of America).

[0013] In this specification, the strains with accession numbers beginning with the words NBRC are registered trademarks of the National Institute of Technology and Evaluation (NITE) (Postal Code: 292-0818, Address: 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan). This is a number given to microorganisms stored in the National Institute of Informatics (NII) and can be obtained from the Institute.

[0014] In this specification, the strains having accession numbers beginning with the word DSM are registered with the Deutsche Sammlung von This is the number assigned to the microorganisms stored at Mikroorganismen und Zellkulturen GmbH (Inhoffenstr. 7B 38124 Braunschweig Germany) and can be obtained from the institution.

[0015] <1> The Streptomyces of the present invention Streptomyces ) genus bacteria The Streptomyces bacterium of the present invention comprises a modified phpR gene and a physiologically active CP binding gene. Any bacterium belonging to the genus Streptomyces may be used as long as it has the ability to produce an active substance. As a physiologically active substance having CP bonds, There is no particular limitation as long as the compound has a CP bond that can be used. L-glufosinate, dehydrophos, and phosphopyruvate are biosynthesized from phosphonopyruvate, which is a common intermediate in the synthetic pathway and has a CP bond. Examples of physiologically active substances with CP bonds include fosfomycin and FR900098. .

[0016] Streptomyces bacteria have the inherent ability to produce physiologically active substances that have CP bonds. The bacterium of the present invention may be a Streptomyces bacterium inherently capable of producing a physiologically active substance having a CP bond, or may be modified using a mutation method or DNA recombinant technology to have the ability to produce a physiologically active substance having a CP bond (for example, Non-Patent Documents 1 and 2). In a bacterium, or in a streptomycete which has been given the ability to produce a physiologically active substance having a CP bond, By introducing a modified phpR gene into the bacteria of the genus Salmonella, it was possible to produce a physiologically active compound having a CP bond. This can be achieved by increasing the production of quality.

[0017] The term "ability to produce a physiologically active substance having CP binding" refers to the ability to produce a physiologically active substance having CP binding when the bacterium is cultured in a culture medium. In this case, CP is present in the medium and / or the cells to such an extent that it can be recovered from the medium and / or the cells. It may refer to the ability of a bacterium of the genus Streptomyces to produce and accumulate a physiologically active substance having a binding site.

[0018] "Bialaphos" is also known as phosphinothricin tripeptide (PTT) and is a phosphinothricin (PT) compound consisting of two molecules of L-alanine and one molecule of the amino acid. Bialaphos has the following chemical formula:

[0019] [ka]

[0020] The term "bialaphos" is not limited to the free form of bialaphos, but may also include its salts or hydrates, or adducts formed by bialaphos and other organic or inorganic compounds. That is, the term "bialaphos" may, for example, mean the free form of bialaphos or a hydrate or adduct of bialaphos. The term "bialaphos" may, for example, include salts such as sodium salt, potassium salt, ammonium salt, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride, and internal salts such as zwitterions of bialaphos acid.

[0021] The phpR gene is known to encode a transcription factor of the bialaphos synthesis gene cluster and activates the pmi promoter in the bialaphos synthesis gene cluster shown in FIG. 1. It is believed to contribute to the activation of genes from pmi to phsA.

[0022] Therefore, by introducing the modified phpR gene, as shown in Figure 2, not only bialaphos (shown as PTT in Figure 2) but also L-glufosinate, the precursor of bialaphos, and bialaphos It is also believed that the synthesis of physiologically active substances with CP bonds, such as dehydrophos, fosfomycin, and FR900098, which are branched from the phos biosynthetic pathway, is improved. Figure 2 is based on the results reported in Blodgett et al. 2016, J Antibiot (Tokyo). 69, 15-25. This is a diagram.

[0023] L-glufosinate is the compound shown below, which is widely used as a pesticide. When two molecules of alanine are combined with L-glufosinate, it becomes bialaphos. The cyanate may include, for example, sodium salts, potassium salts, ammonium salts, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride salts, and the like, as well as internal salts such as zwitterions.

[0024] [ka]

[0025] Dehydrophos is the following compound, which has been reported as a fungicide (Circello BT et al., 2010, Chemistry & Biology, 17, 402-411). For example, it may include sodium salts, potassium salts, ammonium salts, monohydrates, dihydrates, trihydrates, monohydrochlorides, dihydrochlorides, and other salts, as well as internal salts such as zwitterions.

[0026] [ka]

[0027] Fosfomycin is the following compound, which has been reported as an antibiotic (Kim SY et al., 2012, Antimicrobial Agents and Chemotherapy, 56, 4175-4183). Fosfomycin may include, for example, sodium salt, potassium salt, ammonium salt, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride, and other salts, as well as inner salts such as zwitterions.

[0028] [ka]

[0029] FR900098 is the following compound, which is expected to be a candidate for an antimalarial drug (Eliot AC et al., 2008, Chem. Biol. 15, 765-770). FR900098 may include, for example, salts such as sodium salt, potassium salt, ammonium salt, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride, and inner salts such as zwitterions.

[0030] [ka]

[0031] The Streptomyces bacterium of the present invention is not particularly limited, but may be, for example, Streptomyces viridochromogenes ( Streptomyces viridochromogenes ), a bacterium belonging to the group Streptomyces hygroscopicus ( Streptomyces hygroscopicus ), a bacterium belonging to the Streptomyces luridus ), a bacterium belonging to the family Streptomyces ruberomulinas (Streptomyces rubellomurinus ) bacteria. Among these, bacteria belonging to Streptomyces viridochromogenes or Streptomyces hygroscopicus are preferred, and bacteria belonging to Streptomyces viridochromogenes are more preferred. These naturally have bialaphos-producing ability and are capable of producing physiologically active substances with CP bonds. The bacterium of the genus Streptomyces is preferably a bacterium having the ability to

[0032] Examples of bacteria belonging to Streptomyces viridochromogenes include Streptomyces viridochromogenes JCM4977 strain, Tue57 strain (Weitnauer, G. et. al., (2002). Microbiology, 148(2), 373-379.), subsp. Komabensis (ATCC29814 strain), and subsp. sulfomycini (NBRC13830) strain. Bacteria belonging to Streptomyces hygroscopicus include Streptomyces hygroscopicus subsp. hygroscopicus (ATCC21589), subsp. ascomyceticus (ATCC14891), subsp. yingchengensis (Qin, Z. et al. (1994). J. Bacterial., 176(7), 2090-2095.), subsp. limoneus (ATCC21431), subsp. duamyceticus (JCM4427), subsp. enhygrus (DSM41913), subsp. crystallogenes (NBRC16551), subsp. azalomyceticus (ATCC13810), subsp. jinggangensis (Yu, Y. et al., (2005). Appl. Environ. Microbiol., 71(9), 5066-5076.), subsp. aabomyceticus (ATCC21449) strain, and subsp. hialomyceticus (NBRC13946) strain.

[0033] <2> Modified phpR gene The bacterium of the present invention comprises a modified phpR gene. The modified phpR gene is a gene encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO:1 or an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO:1.

[0034] The "polypeptide consisting of the amino acid sequence of SEQ ID NO: 1" is a protein encoded by the phpR gene of Streptomyces viridochromogenes (Genbank Accession No. It is known as a transcription factor that controls the gene expression of the bialaphos synthesis gene cluster.

[0035] A "polypeptide consisting of an amino acid sequence having 90% or more identity with the amino acid sequence of SEQ ID NO: 1" is an analog protein in which a part of the amino acid sequence of SEQ ID NO: 1 has been subjected to a substitution, deletion, insertion, and / or addition mutation, and preferably has activity as a transcription factor of the bialaphos synthesis gene cluster (Non-Patent Documents 3, 4). A "polypeptide consisting of an amino acid sequence having 90% or more identity with the amino acid sequence of SEQ ID NO: 1" may be a polypeptide consisting of an amino acid sequence having 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identity with the amino acid sequence of SEQ ID NO: 1. The number of mutations in an analog protein depends on the position of the amino acid residue in the three-dimensional structure of the protein or the type of amino acid residue. The number of mutations in an analog protein is not strictly limited, but may be 1 to 30 in the amino acid sequence of SEQ ID NO: 1. In some cases, it may be 1-20, in other cases, 1-15, in other cases, 1-10, or in other cases, 1-5. That's fine.

[0036] The modified phpR gene has the same codons as the natural phpR gene, UUC for phenylalanine and UUC for leucine. is CUG or CUC, isoleucine is AUC, valine is GUC or GUG, serine is UCG or UCC, or AGC, proline to CCG or CCC, threonine to ACC or ACG, alanine to GCC or GCG, tyrosine to UAC, histidine to CAC, glutamine to CAG, asparagine to AAC, lysine to AAG, aspartic acid to GAC, glutamic acid to GAG, cysteine ​​to UGC, arginine to CGC or CGG, glycine to GGC, and the stop codon to UGA (hereinafter, "codon modification"). "), and preferably, phenylalanine is UUC, leucine is CUG, isoleucine is AUC, valine is GUC, serine is UCG, proline is CCG, and threonine is ACC. Alanine is GCC, tyrosine is UAC, histidine is CAC, glutamine is CAG, asparagine is AAC, lysine is AAG, aspartic acid is GAC, glutamic acid is GAG, cysteine ​​is UGC, and alginate is GCC. The codons that code for each amino acid are CGC for ginine, GGC for glycine, and UGA for the stop codon. These codons tend to be used frequently in Streptomyces viridochromogenes, and the expression level of the phpR gene in Streptomyces bacteria is optimized, resulting in the expression of CP In other words, the modified phpR gene is a combination of codons that optimizes the expression of the natural phpR gene in Streptomyces bacteria, thereby improving the ability to produce a physiologically active substance having a CP bond. It is a gene that has been modified to use such codons.

[0037] The modified phpR gene is preferably a polynucleotide containing the nucleotide sequence of SEQ ID NO: 2. The nucleotide sequence of SEQ ID NO: 2 is a nucleotide sequence obtained by subjecting the wild-type phpR gene of Streptomyces viridochromogenes to the above-mentioned preferred codon modification.

[0038] Incidentally, "codon" refers to the arrangement of three nucleotides in mRNA. In the process of converting information from nucleotides to amino acids, three bases form one unit and are translated into one amino acid. Since 64 types of codons correspond to 20 types of amino acids, there is degeneracy in the genetic code, and one amino acid has one to six types of synonymous codons. Specifically, there are two codons for phenylalanine, UUU and UUC; six codons for leucine, UUA, UUG, CUU, CUC, CUA and CUG; three codons for isoleucine, AUU, AUC and AUA; one codon for methionine, AUG; four codons for valine, GUU, GUC, GUA and GUG; and one codon for serine, UCU, UCC, UCA and U. There are six codons for proline: CCU, CCC, CCA, CCG; four codons for threonine: ACU, ACC, ACA, ACG; four codons for alanine: GCU, GCC, GCA, GCG; two codons for tyrosine: UAU and UAC; two codons for histidine: CAU and CAC; and one codon for glutamine: CAA. There are two codons for asparagine, AAU and AAC, and for lysine, AAU and AAC. There are two codons for ribozyme, AAA and AAG; two codons for aspartic acid, GAU and GAC; two codons for glutamic acid, GAA and GAG; two codons for cysteine, UGU and UGC; one codon for tryptophan, UGG; and one codon for arginine, UGG. There are six codons for ginine: CGU, CGC, CGA, CGG, AGA, and AGG, and four codons for glycine: GGU, GGC, GGA, and GGG. There are also three stop codons: UAA, UAG, and UGA. There are different types. In the modified phpR gene, when there are multiple synonymous codons, one of the above is used. Specifically, the codons for phenylalanine are UUC, for leu leucine is CUG or CUC, isoleucine is AUC, valine is GUC or GUG, serine is UCG, UCC or AGC, proline is CCG or CCC, threonine is ACC or ACG, alanine is GCC or is GCG, tyrosine is UAC, histidine is CAC, glutamine is CAG, asparagine is AAC, and lysine is The codons AAG, GAC, GAG, UGC, CGC or CGG, CGC or GGG, GGC, and UGA are used as the stop codons, and preferably UUC for phenylalanine, UUC for leucine, AUC for isoleucine, GUC for valine, UCG for serine, UCG for proline, and UGG for glycine. Phosphorus is CCG, threonine is ACC, alanine is GCC, tyrosine is UAC, histidine is CAC, and glutamate is Glu. The codons used are CAG for cysteine, AAC for asparagine, AAG for lysine, GAC for aspartic acid, GAG for glutamic acid, UGC for cysteine, CGC for arginine, and GGC for glycine, and UGA for the stop codon. It is used.

[0039] The term "natural phpR gene" refers to the phpR gene before the above-mentioned codon modification is performed. The natural phpR gene encodes a polypeptide consisting of an amino acid sequence identical to the amino acid sequence encoded by the modified phpR gene. Thus, the natural phpR gene is a gene that encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more identity with the amino acid sequence of SEQ ID NO: 1 and that can function as a transcription factor of the bialaphos synthesis gene cluster.

[0040] An example of a natural phpR gene is the phpR gene of Streptomyces viridochromogenes, also known as the prpA gene. The phpR gene of Streptomyces viridochromogenes has the nucleotide sequence of SEQ ID NO:3 and encodes a polypeptide containing the amino acid sequence of SEQ ID NO:1.

[0041] <3> Enhancement of production of bioactive substances with CP binding The bacterium of the present invention contains a modified phpR gene, and is therefore capable of producing a physiologically active substance having a CP bond. is an enhanced bacterium. The modified phpR gene can be prepared by methods well known to those skilled in the art, for example, it can be obtained as a synthetic gene by elongating it using PCR (assembly PCR) in combination with synthetic oligo DNA.

[0042] The method of introducing the modified phpR gene into a bacterium of the genus Streptomyces is not limited, but for example, the modified phpR gene can be increased by introducing the modified phpR gene into the chromosome of the bacterium and / or introducing an autonomously replicating plasmid containing the modified phpR gene into the bacterium. Such introduction into a bacterium of the genus Streptomyces can be carried out by genetic engineering techniques well known to those skilled in the art.

[0043] Examples of vectors include, but are not limited to, plasmids such as pGM1190, pSET152, pKC1139, SCP2, SLP1.2, and pIJ101. The modified phpR gene can be expressed, for example, by homologous recombination, etc. The modified phpR gene can also be introduced into the chromosomal DNA of bacteria by For example, multiple copies of the modified phpR gene can be introduced into the chromosomal DNA by performing homologous recombination using a sequence having multiple copies in the chromosomal DNA. Examples of such DNA include, but are not limited to, the interleukin-1 (IL-1) domains at the ends of repetitive DNA and transposable elements. Furthermore, by incorporating the modified phpR gene into a transposon and transferring it, multiple copies of the gene can be introduced into chromosomal DNA.

[0044] Furthermore, a wild-type and / or modified foreign expression control region may be introduced upstream and / or downstream of the modified phpR gene. The expression control region may include a promoter, an enhancer, an attenuator and a termination signal, an antitermination signal, a ribosome binding site (RBS), and other expression control elements (e.g., a repressor or inducer). and / or, for example, binding sites for transcriptional and translational regulatory proteins in the transcribed mRNA). Modification of the expression control region may be combined with an increase in the copy number of the modified phpR gene.

[0045] An example of a promoter suitable for enhancing the expression of the modified phpR gene is, for example, a promoter having the nucleotide sequence of SEQ ID NO: 4 (Genbank accession number: WP_003988467.1 upstream region of the gene encoding the protein), lac promoter, trp promoter, trc promoter, tac promoter, tet promoter, araBAD promoter, rpoH promoter Examples of promoters include the msrA promoter, the msrA promoter, the Pm1 promoter (from the genus Bifidobacterium), and the PR and PL promoters of lambda phage.

[0046] Preparation of plasmid DNA, DNA cleavage, DNA ligation, DNA transformation, selection of oligonucleotides as primers, introduction of mutations, etc. Methods for cloning may be conventional methods well known to those skilled in the art. Such methods are described, for example, in Sambrook J., Fritsch EF and Maniatis T., "Molecular Cloning: Laboratory Manual”, 2nd ed., Cold Spring Harbor Laboratory Press (1989), or Green MR and Sambrook JR, “Molecular Cloning: A Laboratory Manual”, 4th ed., Cold Spring Harbor Laboratory Press (2012), or Bernard R. Glick, Jack J. Pasternak and Cheryl L. Patten, “Molecular Biotechnology: principles and applications of recombinant DNA”, 4th ed., Washington, DC, ASM Press (2009).

[0047] Recombinant DNA manipulation techniques include, for example, transformation, transfection, and immunization. Any method can be used, including conventional methods such as transformation, transfection, infection, conjugation, or mobilization of bacteria with DNA encoding the protein. By this, the bacterium is endowed with the ability to synthesize the protein encoded by the DNA. Methods of transformation, transfection, infection, conjugation, and mobilization can include any method.

[0048] In addition to the above-mentioned properties, the bacteria may have specific properties such as various nutritional requirements, drug resistance, drug sensitivity, drug dependency, etc., without departing from the scope of the present invention.

[0049] The copy number of the modified phpR gene, the presence or absence of the gene, e.g., restricts chromosomal DNA. After processing, the gene sequence can be detected by Southern blotting using a probe based on the gene sequence, or by fluorescence in situ hybridization (FISH), etc. The level of gene expression can be determined by measuring the amount of mRNA transcribed from the gene using a variety of well-known methods, such as Northern blotting or quantitative RT-PCR.

[0050] "The production of a physiologically active substance having a CP bond is enhanced" means that the cell containing the modified phpR gene In bacteria, the number of bioactive substances with CP binding was higher than that of bacteria without the modified phpR gene. Specifically, for example, a bacterium containing a modified phpR gene produces 1.1 times or more, 1.3 times or more, or 1.5 times or more of a physiologically active substance having a CP bond in a medium and / or in a bacterial cell, compared with a bacterium not containing a modified phpR gene. The term "bacteria not containing a modified phpR gene" may refer to a bacterial strain that can be a control for the above comparison. Examples of the bacterial strain include wild-type strains and parent strains of bacteria belonging to the genus Streptomyces (e.g., Streptomyces viridochromogenes). A specific example of a non-modified bacterial strain is the Streptomyces viridochromogenes JCM4977 strain. The physiologically active substance having a CP bond, the production of which is enhanced, may be a physiologically active substance having one or more types of CP bonds.

[0051] The production amount of a physiologically active substance having a CP bond, such as bialaphos, can be measured by a known method. For example, a physiologically active substance having a CP bond that has accumulated in the medium or in the bacterial cells can be measured by LC-MS / MS.

[0052] <4> Method for producing a physiologically active substance having a CP bond according to the present invention The method for producing a physiologically active substance having a CP bond of the present invention is carried out by using the Streptomyces sp. Bacteria are cultured in a culture medium, and bioactive substances with CP binding are detected in the culture medium and / or in the bacteria. The physiologically active substances having CP bonds include those mentioned above. The biologically active substances having a CP bond can be produced in particular in the free form or in the form For example, a physiologically active substance having a CP bond may be prepared as a salt or a mixture thereof. Salts such as sodium, potassium, ammonium, etc. of the compound can be prepared by the above method.

[0053] In addition, the method for producing a physiologically active substance having a CP bond of the present invention is Bacteria of the genus Sesbacterium were cultured in a culture medium to identify CP-binding physiological species in the culture medium and / or in the cells. After the active substance is produced and accumulated, the CP bond is extracted from the culture medium and / or the cells. The method may optionally include a step of purifying the bioactive substance having CP binding from the culture medium and / or the bacterial cells.

[0054] Cultivation of bacteria and optionally recovery of CP-binding bioactive substances from the medium, etc. The purification and purification processes are the same as those of conventional fermentation methods that use microorganisms to produce bioactive substances with CP bonds. The culture medium may be a synthetic or natural medium, such as a typical medium containing a carbon source, a nitrogen source, a sulfur source, a phosphorus source, inorganic ions, and other organic and inorganic components as required. Carbon sources include glucose, sucrose, lactose, galactose, fructose, arabinose, maltose, xylose, trehalose, lysine, and the like. Examples of the nitrogen sources that can be used include sugars such as maltose and starch hydrolysates, alcohols such as ethanol, glycerol, mannitol, and sorbitol, organic acids such as gluconic acid, fumaric acid, citric acid, malic acid, and succinic acid, and fatty acids. Examples of the nitrogen sources that can be used include inorganic ammonium salts such as ammonium sulfate, ammonium chloride, and ammonium phosphate, organic nitrogen such as soybean hydrolysates, ammonia gas, and aqueous ammonia. In addition, peptone, yeast extract, meat extract, malt extract, corn steep liquor, cottonseed cake, and the like can also be used. The medium can contain one or more of these nitrogen sources. Examples of sulfur sources include ammonium sulfate, magnesium sulfate, iron sulfate, manganese sulfate, and the like. The medium may contain a phosphorus source in addition to the carbon source, nitrogen source, and sulfur source. Examples of phosphorus sources that can be used include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and phosphate polymers such as pyrophosphate. Vitamins such as vitamin B1, vitamin B2, vitamin B6, nicotinic acid, nicotinamide, and vitamin B12, and other necessary substances, such as adenine, nucleic acids such as RNA, amino acids, peptones, casamino acids, and organic nutrients such as yeast extract, can be present in appropriate amounts (even trace amounts). In addition to these, small amounts of calcium phosphate, iron ions, manganese ions, and the like may be added if necessary.

[0055] The cultivation is carried out under conditions suitable for the cultivation of bacteria used in the production method of a physiologically active substance having a CP bond. For example, the culture can be carried out under aerobic conditions for 16 to 72 hours, or 16 to 24 hours. The culture temperature during the culture can be controlled within the range of 28 to 45° C., or 28 to 37° C. The pH can be adjusted between 5 and 8, or between 6 and 7.5. The pH can be adjusted by using an inorganic or organic acidic or alkaline substance, such as urea, calcium carbonate, or ammonia gas.

[0056] After the culture, the physiologically active substance having a CP bond can be collected from the culture medium. After the cultivation, a physiologically active substance having a CP bond can be collected from the bacterial cells. The cells are disrupted, solid matter such as the cells and cell-disrupted suspension (also called cell debris) is removed to obtain the supernatant, from which the physiologically active substance having a CP bond can be recovered. The removal of solids can be carried out by, for example, centrifugation or membrane filtration. The recovery of a physiologically active substance having a CP bond from a culture medium or a supernatant can be carried out by, for example, concentration, crystallization, ion exchange, or the like. This can be carried out by conventional techniques such as conversion chromatography, medium or high pressure liquid chromatography, or a combination thereof.

[0057] The recovered physiologically active substance having a CP bond may contain, in addition to the physiologically active substance having a CP bond, for example, bacteria, medium components, water, metabolic by-products of the microorganism, etc. The biologically active substance having the bond may be purified to a desired degree. The purity of the physiologically active substance may be, for example, 50% or more, preferably 85% or more, and particularly preferably 95% or more. EXAMPLES

[0058] Examples of the present invention will be described below, but the present invention is not limited to these examples.

[0059] [Example 1] We created a strain of Streptomyces viridochromogenes by introducing an autonomously replicating plasmid containing a modified phpR gene (a strain with an autonomously replicating plasmid containing a modified phpR gene) and a strain of Streptomyces viridochromogenes by introducing an autonomously replicating plasmid containing the native phpR gene (a strain with an autonomously replicating plasmid containing the native phpR gene), and evaluated the bialaphos productivity in these strains.

[0060] (1) Construction of plasmid for gene transfer The modified phpR gene (a polynucleotide consisting of the base sequence of SEQ ID NO:5) was chemically synthesized using the artificial gene synthesis service provided by FASMAC Corporation. In addition, Streptomyces viridochromogenes ( S. viridochromogenes ) JCM4977 strain The genomic DNA of the above was used as a template, and the I-257 primer (SEQ ID NO: 6) and I-252 primer (SEQ ID NO: 7) were used. The native phpR gene was amplified by PCR using the sequence shown in column 7).

[0061] The genomic DNA of Streptomyces viridochromogenes JCM4977 strain was used as a template, and the I-67 primer (SEQ ID NO: 8) and I-68 primer (SEQ ID NO: 9) were used to perform PCR. The promoter region (Genbank accession number: WP_003988467.1) encodes the protein The upstream region of the gene (SEQ ID NO: 4) was amplified.

[0062] In addition, the transcription terminator region (sequence number 14) derived from pSET152 (Creative Biogene, Cat. No. OVT2796) having the base sequence shown in Table 2 was amplified by PCR using the I-54 primer (sequence number 10) and the I-55 primer (sequence number 11).

[0063] The apramycin resistance gene of the autonomously replicating plasmid pGM1190 (addgene, #69994) was Specifically, inverse PCR was performed using pGM1190 as a template and I-44 primer (SEQ ID NO: 12) and I-45 primer (SEQ ID NO: 13) to insert the apramycin resistance gene into the pGM1190 plasmid (pGK) in order to replace the drug resistance marker. The resulting DNA fragment was digested with NsiI and SpeI while deleting the nucleotide sequence. The kanamycin resistance gene was inserted into the NsiI-SpeI fragment. The gene was synthesized by FASMAC using an artificial gene synthesis service. The kanamycin resistance gene fragment (SEQ ID NO: 15) shown in Table 2 was used as a template, and the I-137 primer (SEQ ID NO: 15) was used as a template. The gene was prepared by amplifying the gene by PCR using primer number 20) and I-138 primer (sequence number 21).

[0064] The modified phpR gene was inserted by inserting the amplified XbaI-NsiI fragment of the promoter region, the NsiI-SpeI fragment of the modified phpR gene or the NsiI-SpeI fragment of the native phpR gene, and the amplified XbaI-HindIII fragment of the transcription terminator region from pSET into the EcoRI-HindIII gap of pGK. An autonomously replicating plasmid carrying the phpR gene and an autonomously replicating plasmid carrying the native phpR gene were constructed, respectively.

[0065] The primers used are shown in Table 1.

[0066] [Table 1] In the table, the base sequences are from left to right from the 5' end to the 3' end.

[0067] [Table 2] In the table, the base sequences are from left to right from the 5' end to the 3' end.

[0068] (2) Transformation of E. coli for conjugation Using the constructed plasmid, Escherichia coli was transformed by electroporation according to the following procedure. First, competent cells of the E. coli S17-1 strain were prepared by the following procedure. Streaking the glycerol stock of E. coli S17-1 on an LB plate, then incubating at 37°C for 16-20 hours. A single colony was obtained by inoculating the single colony into 2.5 mL of LB medium and incubated at 37 °C. The mixture was pre-cultured at 37°C, 200 rpm for 16 hours. 200 μl of the pre-culture was inoculated into 20 mL of LB medium and incubated at 37°C, 200 rpm for 16 hours at OD 600 The bacteria were harvested by centrifugation (4°C, 3000 xg, 10 min). Then, discard the supernatant, add 20 mL of ice-cold sterile water, and gently suspend the pellet with a pipette. After repeating the steps of collecting and washing the bacteria once more, the bacteria were collected again by centrifugation (4°C, 3000 xg, 10 min), the supernatant was discarded, and the pellet was gently suspended in 200 μl of ice-cold 10% glycerol using a pipette. 50 μl of this suspension was added to each tube (Eppendorf tube). Competent cells of the S17-1 strain were prepared by dispensing the cells into a culture flask (manufactured by Eppendorf).

[0069] The constructed plasmid (~2 μL) was added to the prepared competent cells and electroporated. The cells were transferred to a poration cell (Bio-Rad Laboratories, Inc.) and then left to stand on ice for 10 minutes. An electric pulse of 1.8 kV, 25 μF, and 200 Ω was applied, and 1 mL of LB medium was added. The cells were then harvested at 20,000 xg for 1 minute, the supernatant was removed, and the cells were resuspended in an appropriate amount of medium and plated on 2xYT agar medium containing 100 μg / mL kanamycin. The mixture was then smeared onto the soil and incubated overnight at 37°C. In addition, the same procedure was followed except that an empty vector (pGK) was used instead of the constructed plasmid. E. coli was transformed in each order and cultured as a negative control.

[0070] (3) Transformation of Streptomyces bacteria The transformed E. coli was used to transform Streptomyces bacteria by conjugal transfer according to the following procedure. The E. coli carrying the transformation plasmid obtained by the above culture was inoculated into 2 mL of LB medium containing 100 μg / mL kanamycin and precultured overnight at 37°C and 200 rpm. 100 μL of the preculture was inoculated into 10 mL of fresh LB medium (containing 100 μg / mL kanamycin) and the OD 600 The cells were harvested at 8000 xg for 10 minutes, the supernatant was discarded, and the harvested cells were suspended (washed) in 10 mL of LB medium by pipetting. This was repeated twice to remove antibiotics contained in the culture medium. The collected bacterial pellet was then resuspended in 1 mL of LB medium. 500 μL of this E. coli suspension was then added to 2 mL of 500 μL of LB medium. The cells were suspended in ×YT medium, heat-shocked at 50°C for 10 minutes, and then left to stand on ice. Streptomyces viridochromogenes ( S. viridochromogenes ) JCM4977 strain Biala The strain was mixed with spores of a strain that had one additional copy of the phosphatase gene cluster (see reference example below). The spores were plated on 20 ml of ISP4 medium (2% by weight agar, 1% by weight denatured 100% ethanol). 0.2% by weight calcium carbonate, 0.2% by weight ammonium sulfate, 0.1% by weight dipotassium hydrogen phosphate, 0.1% by weight magnesium sulfate heptahydrate, 0.1% by weight sodium chloride, 0.1% by weight The actinomycetes were plated on a medium containing 0.0001% by weight yeast extract, 0.0001% by weight iron (II) sulfate heptahydrate, 0.0001% by weight manganese chloride heptahydrate, and 0.0001% by weight zinc sulfate heptahydrate, and then cultured at 28°C for approximately two weeks to obtain the culture medium. After the centrifugation, the supernatant was discarded, leaving about 50 μL, and the bacterial pellet was resuspended in the remaining supernatant, and then a dilution series was prepared with sterile water. 100 μL was applied to 20 ml of ISP4 plate medium and cultured overnight at 28°C. 0.5 mg of nalidixic acid and 10 μL of 100 μg / mL kanamycin were added to 1 ml of sterile water, The culture medium was overlaid and cultured at 28°C for an additional 3 to 5 days to obtain Streptomyces transformants (strains carrying an autonomously replicating plasmid with a modified phpR gene inserted, strains carrying an autonomously replicating plasmid with a native phpR gene inserted, and strains carrying an empty vector).

[0071] (4) Flask culture The obtained transformants were cultured on YS medium containing 12.5 ppm kanamycin (1% by weight The bacteria was inoculated into a 500-ml baffled flask containing 150 ml of soluble starch and 0.2% by weight yeast extract, and precultured at 140 rpm and 28°C for 3 days. MYG medium containing 1% by weight malt extract, 0.4% by weight yeast extract, 0.4% by weight glucose The bacteria were inoculated into a 500-ml baffled flask containing 150 ml of the culture medium and cultured at 28° C. for 6 days. The rotation speed was 140 rpm until the third day of culture, and 85 rpm thereafter.

[0072] (5) Measurement of Bialaphos concentration After flask cultivation, the culture medium was sampled and appropriately diluted, and the concentration of bialaphos was measured by LC-MS / MS using a calibration curve prepared based on bialaphos with known concentrations.

[0073] (6) Results The bialaphos productivity of the transformants is shown in Figure 3. As shown in Figure 3, it was confirmed that the productivity of bialaphos in the strain into which the autonomously replicating plasmid with the modified phpR gene was introduced increased by about 1.5 times compared to the negative control, and increased by about 2 times compared to the strain into which the autonomously replicating plasmid with the native phpR gene was introduced.

[0074] [Example 2] A strain in which the modified phpR gene was introduced into the genome of Streptomyces viridochromogenes (modified phpR gene genome-introduced strain) was constructed, and the productivity of bialaphos in the strain was evaluated.

[0075] (1) Construction of plasmid for gene transfer The plasmid for gene introduction into the genome was constructed based on pKC1139 (Nova Lifetech, Catalog No. PVT6009). The gene was introduced into a gene encoding a protein annotated as type I polyketide synthase (Genbank accession number: WP_039933327.1). To carry out this procedure, the upstream and downstream genomic regions of the gene were cloned using I-122 (sequence SEQ ID NO: 16) and I-123 (SEQ ID NO: 17), I-124 (SEQ ID NO: 18) and I-125 (SEQ ID NO: No. 19) primers were used to detect the genomic DNA of Streptomyces viridochromogenes JCM4977 strain. The gene was amplified by PCR using the genome as a template.

[0076] The EcoRI-SpeI fragment of the downstream genomic region was inserted into the EcoRI-XbaI gap of pKC1139. The plasmid thus obtained was cleaved with EcoRI-XbaI, and an EcoRI-SpeI fragment of a kanamycin resistance gene cassette was inserted therein. The kanamycin resistance gene cassette was prepared by cleaving pGK prepared in Example 1 above as a template with the I-137 primer (SEQ ID NO: 20) and the I-138 primer (SEQ ID NO: 21). The DNA was amplified by PCR using the above. The resulting plasmid was cleaved with EcoRI-XbaI, and the EcoRI-SpeI fragment of the "autonomously replicating plasmid with the modified phpR gene inserted" prepared in "(1) Construction of a plasmid for gene introduction" in Example 1 was inserted. Finally, the resulting plasmid was cleaved with EcoRI-XbaI, and the EcoRI-SpeI fragment of the upstream genomic region was inserted to construct a plasmid for introducing the modified phpR gene.

[0077] (2) Transformation of E. coli for conjugation Using the same procedure as in Example 1, the constructed gene transfer plasmid and empty vector (pKC1139) were each transformed into conjugative E. coli.

[0078] (3) Transformation of Streptomyces bacteria Using the obtained E. coli for conjugation, bacteria of the genus Streptomyces were transformed in the same manner as in Example 1.

[0079] (4) Selection of transformants The obtained transformants were confirmed by colony PCR. - (sequence number 22) and I-138 primer (sequence number 21) were used in combination.

[0080] The base sequences of the primers used are shown in Table 3.

[0081] [Table 3] In the table, the base sequences are from left to right, from the 5' end to the 3' end.

[0082] (5) Flask culture The selected transformants were cultured in flasks in the same manner as in Example 1.

[0083] (6) Measurement of Bialaphos concentration The concentration of bialaphos was measured in the same manner as in Example 1 using the flask-cultured transformants.

[0084] (7) Results The productivity of bialaphos in the transformants is shown in Figure 4. As shown in Figure 4, it was confirmed that the productivity of bialaphos in the strain into which the modified phpR gene was introduced into the genome was increased by about 2.5 times compared to the negative control.

[0085] [Reference example: Creation of a strain with an additional copy of the bialaphos biosynthetic enzyme gene cluster] Streptomyces viridochromogenes JCM4977 was cloned with the bialaphos synthase gene. A strain with one additional copy of star was created by the following procedure. It is known that B. viridochromogenes has the bialaphos synthesis gene cluster shown in Figure 1. The gene cluster contains the 5'-terminal From the side, the phpA gene, the phsB gene, the phpB gene, the phsC gene, the pmi gene, and the phpC gene. phpD gene, phpE gene, ppm gene, ppd gene, phpF gene, phpG gene, phpH gene, phpI gene, phpJ gene, phpK gene, pms gene, phsA gene, pat gene, dea It is known that the phpA gene, the phpL gene, the phpM gene, the phpN gene, and the phpR gene exist (Blodgett et al. 2016, J Antibiot (Tokyo). 69, 15-25).

[0086] (1) Construction of plasmid for gene transfer The plasmid for gene transfer was based on pSET152 (Creative Biogene, Cat. No. OVT2796). The genome DNA of Streptomyces viridochromogenes JCM4977 strain was used as a template to construct the vector. Each DNA fragment of the Sq1 to Sq6 and F3 regions of the bialaphos synthase gene cluster was The primer set shown in Table 4 was used for PCR amplification. First, the XbaI-EcoRV fragment of F3 obtained was inserted into the XbaI-EcoRV gap of pSET152 to construct a plasmid carrying F3 (F3 in Fig. 1). Next, the NheI-SbfI fragment of Sq6 and the SbfI-EcoRV fragment of F3 were inserted into the XbaI-EcoRV gap of pSET152. Next, the MunI-SpeI fragment of Sq5 was inserted into the EcoRI-XbaI gap of the plasmid into which Sq6F3 had been introduced to construct a plasmid into which Sq5-6F3 (Sq5-6F3 in Fig. 1) had been introduced was constructed. Similarly, the MunI-SpeI fragment of Sq4, the MunI-SpeI fragment of Sq3, the MunI-SpeI fragment of Sq2, and the MunI-SpeI fragment of Sq1 were each inserted, and the plasmids shown in Fig. 1 were constructed. The plasmid in which the full length of the bialaphos synthase gene cluster was introduced into pSET152. was constructed.

[0087] [Table 4]

[0088] The base sequences of the primer sets shown in Table 4 are shown in Table 5.

[0089] [Table 5] In the table, the base sequences are from left to right, from the 5' end to the 3' end.

[0090] (2) Transformation of E. coli for conjugation Escherichia coli was transformed with the constructed plasmid in the same manner as in “(2) Transformation of Escherichia coli for conjugation” in Example 1, except that 100 μg / mL apramycin was used as the antibiotic.

[0091] (3) Transformation of Streptomyces bacteria The Streptomyces bacterium to be transformed was Streptomyces viridochromogenes ( S. viridochromogenes The JCM4977 strain was used, and 100 μg / mL apramycin was used as an antibiotic for the culture of E. coli S17-1 strain, and 0.5 mg nalidixic acid and 10 μl of 100 mg / mL apramycin in 1 ml of sterile water were used for the selection of Streptomyces viridochromogenes. A strain containing an additional copy of the bialaphos biosynthetic enzyme gene cluster was obtained by transforming Streptomyces bacteria using the same procedure as in “(3) Transformation of Streptomyces bacteria” in Example 1, except for the addition of ramycin.

Claims

1. A streptococcus having a modified phpR gene and enhanced production of a physiologically active substance having a CP bond. A bacterium belonging to the genus Streptomyces, The modified phpR gene is a gene encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1, The codons of the modified phpR gene are UUC for phenylalanine, CUG or CUC for leucine, Isoleucine is AUC, valine is GUC or GUG, serine is UCG, UCC or AGC, proline is CCG or CCC, threonine is ACC or ACG, alanine is GCC or GCG, and tyrosine is UAC. , histidine is CAC, glutamine is CAG, asparagine is AAC, lysine is AAG, aspartic acid is GAC, glutamic acid is GAG, cysteine ​​is UGC, arginine is CGC or CGG, glycine is GGC, and the stop codon is UGA, in bacteria.

2. The codons of the modified phpR gene are UUC for phenylalanine, CUG for leucine, AUC for isoleucine, GUC for valine, UCG for serine, CCG for proline, ACC for threonine, GCC for alanine, UAC for tyrosine, CAC for histidine, CAG for glutamine, AAC for asparagine, AAG for lysine, GAC for aspartic acid, GAG for glutamic acid, UGC for cysteine, CGC for arginine, and CGC for glutamic acid. The bacterium of claim 1 , wherein the lysine is GGC and the stop codon is UGA.

3. The bacterium according to claim 1 , wherein the modified phpR gene is a polynucleotide comprising the base sequence of SEQ ID NO:

2.

4. 2. The bacterium according to claim 1, which is a bacterium belonging to Streptomyces viridochromogenes or Streptomyces hygroscopicus.

5. The bacterium according to claim 1, wherein the physiologically active substance having a CP bond is one or more selected from the group consisting of bialaphos, L-glufosinate, dehydrophos, fosfomycin, and FR900098.

6. The bacterium according to claim 1 , wherein the physiologically active substance having a CP bond is bialaphos.

7. A method for producing a physiologically active substance having a CP bond, comprising the steps of: A production method comprising culturing the bacterium according to any one of claims 1 to 6 in a culture medium to produce and accumulate bialaphos in the culture medium and / or the bacterial cells.